AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17545208 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy individuals) performing the same shape-tracing task.
Number of subjects: 22
Study 14970111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg TID
Number of subjects: 38
Study 11477352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (2 doses, 6 months apart)
Number of subjects: 37
Study 11477352 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control group (n=45)
Number of subjects: 37
Study 9570178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate (0.1-0.2 mg)
Number of subjects: 25
Study 9570178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7520643 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 832
Study 7520643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 832
Study 3052462 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + Ambroxol (TA) - 700 mg theophylline, 60 mg ambroxol/d for 5 days
Number of subjects: 19
Study 3052462 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol (A) - 60 mg ambroxol/d for 5 days
Number of subjects: 19
Study 4609556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hexachlorophane
Number of subjects: 0
Study 4609556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% Irgasan DP 300 bar soap
Number of subjects: 0
Study 4609556 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated bar soap
Number of subjects: 0
Study 4609556 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine detergent solution
Number of subjects: 0
Study 4609556 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hexachlorophane detergent cream
Number of subjects: 0
Study 4609556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Irgasan DP 300 detergent solution
Number of subjects: 0
Study 28455158 — intervention group
Group type: EXPERIMENTAL
Intervention: sedated EGD (sEGD)
Number of subjects: 209
Study 28455158 — intervention group
Group type: COMPARATOR
Intervention: hospital unsedated transnasal endoscopy (huTNE)
Number of subjects: 209
Study 28455158 — intervention group
Group type: COMPARATOR
Intervention: mobile unsedated transnasal endoscopy (muTNE)
Number of subjects: 209
Study 28455158 — intervention group
Group type: COMPARATOR
Intervention: unsedated transnasal endoscopy (uTNE)
Number of subjects: 209
Study 28489032 — intervention group
Group type: COMPARATOR
Intervention: Serum 25(OH)D concentrations in critical HFMD group (20.0 ± 8.4 ng/mL)
Number of subjects: 138
Study 28489032 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D deficiency group in critical and severe HFMD
Number of subjects: 138
Study 28489032 — intervention group
Group type: EXPERIMENTAL
Intervention: Death group in critical and severe HFMD
Number of subjects: 138
Study 28489032 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration
Number of subjects: 138
Study 26189433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonafarnib 100 mg twice daily for 28 days (group 1)
Number of subjects: 14
Study 26189433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonafarnib 200 mg twice daily for 28 days (group 2)
Number of subjects: 14
Study 26189433 — intervention group
Group type: COMPARATOR
Intervention: Lonafarnib (both doses)
Number of subjects: 14
Study 23245622 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography screening in group 1 (aged 5-15 years)
Number of subjects: 2004
Study 23245622 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography screening in group 2 (aged 16-18 years)
Number of subjects: 2004
Study 21389753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (COMB) - 8 weekly body-mind-spirit group psychotherapy sessions added to pharmacotherapy
Number of subjects: 63
Study 21389753 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (MT) - pharmacotherapy only
Number of subjects: 63
Study 21389753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (COMB)
Number of subjects: 63
Study 21389753 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (MT)
Number of subjects: 63
Study 18492847 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant milk formula with 6 g/L short-chain galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS)
Number of subjects: 215
Study 18492847 — intervention group
Group type: COMPARATOR
Intervention: Control group (without scGOS/lcFOS)
Number of subjects: 215
Study 16872565 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg GHB (Xyrem) alone
Number of subjects: 16
Study 16872565 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg GHB (Xyrem) combined with 0.6 g/kg ethanol
Number of subjects: 16
Study 16872565 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 14600188 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-216 (recombinant ApoA-I Milano/phospholipid complexes) at 15 mg/kg or 45 mg/kg
Number of subjects: 123
Study 14600188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 14600188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (ETC-216)
Number of subjects: 123
Study 11029136 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer feedback program (PFP)
Number of subjects: 91
Study 11029136 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 91
Study 8609686 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine given to mothers during the third trimester and infants at 2, 3, and 4 months of age
Number of subjects: 451
Study 8609686 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine given to mothers and inactivated poliovirus vaccine to infants
Number of subjects: 451
Study 8609686 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A and C vaccine given to mothers and PRP-T to infants
Number of subjects: 451
Study 8609686 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated mothers
Number of subjects: 451
Study 8609686 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of vaccinated mothers
Number of subjects: 451
Study 8609686 — intervention group
Group type: COMPARATOR
Intervention: Infants of unvaccinated mothers
Number of subjects: 451
Study 1358134 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg/kg
Number of subjects: 20
Study 1358134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 3883685 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol (0.5 mg)
Number of subjects: 0
Study 3883685 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation with specific training for the pain site
Number of subjects: 0
Study 3883685 — intervention group
Group type: COMPARATOR
Intervention: Unspecific relaxation control procedure
Number of subjects: 0
Study 30738680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccination
Number of subjects: 399
Study 30738680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccination
Number of subjects: 399
Study 30738680 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 399
Study 30092413 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited transfer to cardiac arrest center (CAC) with 24/7 access to interventional cardiology facilities, cooling, and goal-directed therapies
Number of subjects: 860
Study 30092413 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (delivery to the nearest emergency department)
Number of subjects: 860
Study 27074066 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression surgery plus fusion surgery (fusion group)
Number of subjects: 247
Study 27074066 — intervention group
Group type: COMPARATOR
Intervention: Decompression surgery alone (decompression‐alone group)
Number of subjects: 247
Study 25265492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily)
Number of subjects: 423
Study 25265492 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib and placebo
Number of subjects: 423
Study 22356216 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 8
Study 22356216 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4 mm)
Number of subjects: 8
Study 22356216 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME (10 mm)
Number of subjects: 8
Study 22356216 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + L-NAME (4 mm + 10 mm)
Number of subjects: 8
Study 21161118 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant anchorage assisted self-ligating appliance (G1)
Number of subjects: 20
Study 21161118 — intervention group
Group type: COMPARATOR
Intervention: Self-ligating appliance (G2)
Number of subjects: 20
Study 18057680 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (100 mg/Kg) plus phototherapy
Number of subjects: 60
Study 18057680 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 60
Study 15138649 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Sound or music distraction using white noise generators or hearing aids
Number of subjects: 40
Study 15138649 — intervention group
Group type: COMPARATOR
Intervention: Group B: Imagination distraction using light and warmth stimuli
Number of subjects: 40
Study 11441371 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity leg exercises 3 times weekly with weekly increases in resistance combined with 45 minutes of moderate, nonresistance exercise weekly.
Number of subjects: 43
Study 11441371 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise 30 minutes daily, 6 days weekly (self-paced walking program).
Number of subjects: 43
Study 11441371 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity leg exercises 3 times weekly.
Number of subjects: 43
Study 11441371 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity leg exercises 3 times weekly and moderate intensity exercise.
Number of subjects: 43
Study 9604603 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium levels in malnourished children
Number of subjects: 46
Study 9604603 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium levels in marasmic children
Number of subjects: 46
Study 9604603 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum magnesium levels correlation
Number of subjects: 46
Study 8040762 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in prepubertal children
Number of subjects: 90
Study 8040762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual maturation (Tanner stage)
Number of subjects: 90
Study 8040762 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in height and weight
Number of subjects: 90
Study 8040762 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle area
Number of subjects: 90
Study 2471213 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl/6% Dextran 70 (HSD) solution
Number of subjects: 32
Study 2471213 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringers (LR) solution
Number of subjects: 32
Study 31894731 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Palliative Care Needs Rounds
Number of subjects: 1700
Study 30741988 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened version of the EORTC QLQ-BR23 scales
Number of subjects: 10794
Study 30741988 — intervention group
Group type: COMPARATOR
Intervention: Original EORTC QLQ-BR23 scales
Number of subjects: 10794
Study 30113269 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based endovascular revascularisations
Number of subjects: 10000
Study 30113269 — intervention group
Group type: COMPARATOR
Intervention: Open-surgical endarterectomy
Number of subjects: 10000
Study 30113269 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 10000
Study 27177451 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (Xeomin(®))
Number of subjects: 35
Study 27177451 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinum toxin A (Botox(®))
Number of subjects: 35
Study 24829204 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF1 mutations in β-thalassemia patients
Number of subjects: 5029
Study 24829204 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF1 mutations
Number of subjects: 5029
Study 24829204 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF1 mutations in β-thalassemia intermedia patients
Number of subjects: 5029
Study 22336631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 to 7 mg/kg)
Number of subjects: 78
Study 22336631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22336631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 to 7 mg/kg) in participants heterozygous at rs5751876 and rs2298383
Number of subjects: 78
Study 22336631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 to 7 mg/kg) in participants minor homozygous at rs5751876 and rs2298383
Number of subjects: 78
Study 22336631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 to 7 mg/kg) in participants minor homozygous at rs2472304
Number of subjects: 78
Study 20078830 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (1500 mg calcium/day in 3 divided doses)
Number of subjects: 510
Study 20078830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 17610879 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mug oral misoprostol
Number of subjects: 270
Study 17610879 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 270
Study 16291468 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument
Number of subjects: 104
Study 11991447 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 fixed combination (n = 199)
Number of subjects: 583
Study 11991447 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 separate combination (n = 190)
Number of subjects: 583
Study 11991447 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 194)
Number of subjects: 583
Study 11991447 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 treatment (both fixed and separate combinations)
Number of subjects: 583
Study 11991447 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 583
Study 11991447 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 treatment
Number of subjects: 583
Study 10466286 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study 7590047 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy with absolute ethanol
Number of subjects: 62
Study 7590047 — intervention group
Group type: COMPARATOR
Intervention: 0.1% epinephrine and thrombin spray (control group)
Number of subjects: 62
Study 2291869 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg ER once daily
Number of subjects: 28
Study 2291869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6106039 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 55
Study 6106039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 55
Study 30342326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocols for fever, hyperglycaemia, and swallowing management in intervention hospitals.
Number of subjects: 1126
Study 30342326 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous blood glucose taken on admission to hospital or within 2 hours of stroke unit admission.
Number of subjects: 1126
Study 30342326 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-prick blood glucose measured within 72 hours of stroke unit admission.
Number of subjects: 1126
Study 30342326 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing screening or assessment performed within 24 hours of stroke unit admission.
Number of subjects: 1126
Study 29173323 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation within the first hour of birth
Number of subjects: 4203
Study 29173323 — intervention group
Group type: COMPARATOR
Intervention: Delayed breastfeeding initiation (>1 hour after birth)
Number of subjects: 4203
Study 29173323 — intervention group
Group type: COMPARATOR
Intervention: Delayed breastfeeding initiation
Number of subjects: 4203
Study 25711158 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 1 (F1) - microencapsulated fish oil powder
Number of subjects: 47
Study 25711158 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 2 (F2) - microencapsulated fish oil powder
Number of subjects: 47
Study 25711158 — intervention group
Group type: COMPARATOR
Intervention: Fish Oil Gel Capsules (FOGC)
Number of subjects: 47
Study 24121917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning by plasma of Argon (G3)
Number of subjects: 18
Study 24121917 — intervention group
Group type: COMPARATOR
Intervention: Laboratory customization and cleaning by steam (G2)
Number of subjects: 18
Study 24121917 — intervention group
Group type: COMPARATOR
Intervention: No treatment (G1)
Number of subjects: 18
Study 22064267 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinrix™ + MMR + Varicella (V)
Number of subjects: 478
Study 22064267 — intervention group
Group type: COMPARATOR
Intervention: Kinrix™ + MMR
Number of subjects: 478
Study 19191793 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG hydrogel membrane (test group, 19 patients)
Number of subjects: 37
Study 19191793 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane (control group, 18 patients)
Number of subjects: 37
Study 17196327 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant
Number of subjects: 0
Study 17196327 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: High ventilation rate
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: High temperature (> 25.4 degrees C)
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: Long shifts
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: Understaffing
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation rates exceeding ASHRAE Standard 62
Number of subjects: 0
Study 15663459 — intervention group
Group type: EXPERIMENTAL
Intervention: High temperature
Number of subjects: 0
Study 11943530 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group P; n = 20)
Number of subjects: 40
Study 11943530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg IV followed by propofol (Group PF; n = 20)
Number of subjects: 40
Study 9616533 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhaled via Turbuhaler
Number of subjects: 12
Study 9616533 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol inhaled via pMDI
Number of subjects: 12
Study 7613823 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cryptorchid men
Number of subjects: 699
Study 7613823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 699
Study 7613823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cryptorchid men
Number of subjects: 699
Study 7613823 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at orchidopexy
Number of subjects: 699
Study 2115680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-300 mg/day)
Number of subjects: 42
Study 2115680 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (100-300 mg/day)
Number of subjects: 42
Study 2115680 — intervention group
Group type: COMPARATOR
Intervention: Total Sleep Deprivation (TSD) before and after one week of antidepressant medication
Number of subjects: 42
Study 6107585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 60
Study 6107585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30735073 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (3 g/day)
Number of subjects: 86
Study 30735073 — intervention group
Group type: EXPERIMENTAL
Intervention: OO (3 g/day)
Number of subjects: 86
Study 30735073 — intervention group
Group type: COMPARATOR
Intervention: EPA (3 g/day)
Number of subjects: 86
Study 28316177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary hospital guided and community‐driven family self‐help cardiac rehabilitation for 3 months
Number of subjects: 80
Study 28316177 — intervention group
Group type: COMPARATOR
Intervention: Routine secondary treatment for 3 months
Number of subjects: 80
Study 25524534 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH) using Electrosurgical Bipolar Vessel Sealing (EBVS)
Number of subjects: 90
Study 25524534 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Hysterectomy (VH) using Electrosurgical Bipolar Vessel Sealing (EBVS)
Number of subjects: 90
Study 25524534 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH) using Electrosurgical Bipolar Vessel Sealing (EBVS)
Number of subjects: 90
Study 24039917 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning group with case-based teaching
Number of subjects: 63
Study 24039917 — intervention group
Group type: COMPARATOR
Intervention: classroom teaching
Number of subjects: 63
Study 24039917 — intervention group
Group type: COMPARATOR
Intervention: e-learning group with eBook teaching material
Number of subjects: 63
Study 17218227 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial rollerball ablation
Number of subjects: 48
Study 17218227 — intervention group
Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 48
Study 15610889 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic VIH repair
Number of subjects: 314
Study 15610889 — intervention group
Group type: COMPARATOR
Intervention: Open VIH repair
Number of subjects: 314
Study 10811678 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg orally every 8 hours
Number of subjects: 130
Study 10811678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally every 8 hours plus Rifampin 300 mg orally every 12 hours
Number of subjects: 130